(Q46289193)

21 December 2017

title

Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension (English)

1 reference

21 December 2017

0 references

2

Ralf Dechend

1 reference

21 December 2017

Rainer Dietz

1

1 reference

21 December 2017

Chuek-Man Yu

3

1 reference

21 December 2017

Manesh Bheda

4

1 reference

21 December 2017

Jessica Ford

5

1 reference

21 December 2017

Margaret F Prescott

6

1 reference

21 December 2017

Deborah L Keefe

7

1 reference

21 December 2017

publication date

1 September 2008

1 reference

21 December 2017

Journal of the Renin-Angiotensin-Aldosterone System

published in

1 reference

21 December 2017

volume

9

1 reference

21 December 2017

issue

3

1 reference

21 December 2017

page(s)

163-175

1 reference

21 December 2017

Structure-based design of aliskiren, a novel orally effective renin inhibitor

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1470320308096411

Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320308096411

Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320308096411

Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320308096411

Dissociation between renin and arterial pressure responses to beta-adrenergic blockade in human essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320308096411

Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320308096411

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (A

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320308096411

Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320308096411

Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320308096411

Beta-blockers for hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320308096411

New hypertension guidelines from the National Institute for Health and Clinical Excellence and the British Hypertension Society.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320308096411

2007 Guidelines for the Management of Arterial Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320308096411

Plasma renin activity levels in hypertensive persons: their wide range and lack of suppression in diabetic and in most elderly patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320308096411

Is pulse pressure useful in predicting risk for coronary heart Disease? The Framingham heart study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320308096411

Pulse pressure not mean pressure determines cardiovascular risk in older hypertensive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320308096411

Benefits from angiotensin-converting enzyme inhibitor 'beyond blood pressure lowering': beyond blood pressure or beyond the brachial artery?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320308096411

Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320308096411

Effect of chronic diuretic treatment on the plasma renin-angiotensin-aldosterone system in essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320308096411

Aliskiren-binding increases the half life of renin and prorenin in rat aortic vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320308096411

Conformational changes in prorenin during renin inhibition in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320308096411

Newly developed renin and prorenin assays and the clinical evaluation of renin inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320308096411

The diabetogenic potential of thiazide-type diuretic and beta-blocker combinations in patients with hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320308096411

The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320308096411

Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320308096411

Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320308096411

21 January 2018

Identifiers

DOI

10.1177/1470320308096411

1 reference

21 December 2017

1 reference

21 December 2017